Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

by Freeman, C L, Dixon, M, Houghton, R, Kreuzer, K-A, Fingerle-Rowson, G, Herling, M, Humphrey, K, Böttcher, S, de Costa, C S, Iglesias, V, Stilgenbauer, S, Gribben, J, Hallek, M, Goede, V
Published 2016

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

by Fink, A M, Böttcher, S, Ritgen, M, Fischer, K, Pflug, N, Eichhorst, B, Wendtner, C-M, Winkler, D, Bühler, A, Zenz, T, Staib, P, Mayer, J, Hensel, M, Hopfinger, G, Wenger, M, Fingerle-Rowson, G, Döhner, H, Kneba, M, Stilgenbauer, S, Busch, R, Hallek, M
Published 2013